Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Lakewood-Amedex Biotherapeutics / Equity Bottom-Up

Lakewood-Amedex Biotherapeutics (LABT US)

<ul><li>On August 14, 2026, Lakewood-Amedex Biotherapeutics, Inc. (LABT) filed form 10-Q with financial results for the second quarter of 2026.</li><li>Since we initiated coverage on June 23, 2026, Lakewood has continued preparations for the Phase 2a clinical trial of Nu-3 in infected diabetic foot ulcers.</li><li>The study will evaluate 2%, 5%, and 10% concentrations of topical Nu-3 and is intended to provide proof-of-concept data supporting potential advancement into Phase 2b.</li></ul>

On August 14, 2026, Lakewood-Amedex Biotherapeutics, Inc. (LABT) filed form 10-Q with financial results for the second quarter of 2026.Since we initiated coverage on June 23, 2026, Lakewood has continued preparations for the Phase 2a clinical trial of Nu-3 in infected diabetic foot ulcers.The study will evaluate 2%, 5%, and 10% concentrations of topical Nu-3 and is intended to provide proof-of-concept data supporting potential advancement into Phase 2b.

LABT:  Advancing Toward Phase 2a Study of Nu-3 in Infected Diabetic Foot Ulcers